The pCPA teams are currently working on new approaches to our negotiation processes with the goal of supporting timely public drug coverage for Canadian patients.
In the next few weeks, we’ll be sharing information and seeking input on 2 expedited pathways:
- The Early Negotiation Process (ENP): a new pathway designed for cancer drugs being reviewed under the Project Orbis initiative. The ENP is designed to reduce negotiation times by several months. We’ll do this by starting negotiations before a final health technology assessment reimbursement recommendation has been issued by Canada’s Drug Agency. The intent is to have completed negotiations by the time final reimbursement recommendations are published.
- The Targeted Negotiation Process (TNP): a pathway designed for non-complex drug negotiations, including drugs comparable to others already available in the market. We’re introducing revisions to our TNP, which is a streamlined process that’s been available as a negotiation option since 2021.
Check out our website the week of October 20 to learn more about these expedited negotiation pathways. We’ll also be seeking feedback and look forward to providing our partners an opportunity to share their insights with us.
Watch this space for more information in the coming weeks.